// App-Quantinova.ai

663 : Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort

Researchers

Presenter

  • Craig Speziali

Principal Investigators

  • Andrew Daly

  • Mohamed Abuhaleeqa

  • Janet Nitta

  • Yasser Abou Mourad

  • Matthew D. Seftel

  • Kristjan Paulson

Medical Centers

  • Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

  • Department of Medical Oncology and Haematology, CancerCare Manitoba, Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

  • Departments of Medicine and Oncology, Foothills Hospital and Tom Baker Cancer Centre, Calgary, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Hematocrit

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved